Denali Secures FDA Nod for AVLAYAH, Boosts Pipeline with Key Clinical Milestones
Event summary
- FDA approved AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome on March 25, 2026, marking Denali's first commercial product launch.
- First patients treated with AVLAYAH in April 2026, with strong community engagement and operational readiness.
- Denali dosed first patient in Phase 1b study for DNL628 (OTV:MAPT) targeting Alzheimer's disease in March 2026.
- Denali regained full rights to DNL593 (PTV:PGRN) for FTD-GRN after Takeda terminated collaboration, with data expected by end of 2026.
- Denali received $200 million in gross proceeds from Royalty Pharma in March 2026 under a synthetic royalty funding agreement.
The big picture
Denali's FDA approval for AVLAYAH validates its TransportVehicle™ platform, positioning it as a leader in blood-brain barrier crossing technologies. The company's ability to execute on its broad clinical pipeline, particularly in neurodegenerative diseases, will determine its long-term competitive edge in a market hungry for effective CNS therapies. With $1.05 billion in cash as of March 2026, Denali has the financial runway to pursue multiple high-risk, high-reward programs.
What we're watching
- Commercial Execution
- How Denali sustains AVLAYAH's strong launch momentum and achieves payer adoption.
- Pipeline Progress
- Whether DNL593 Phase 1/2 data meets expectations and positions Denali for future partnerships.
- Financial Flexibility
- The pace at which Denali deploys its $200 million funding to advance multiple clinical programs.
Related topics